Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1994;3(6):445–452. doi: 10.1155/S0962935194000633

Differential Proliferative Characteristics of Alveolar Fibroblasts in Interstitial Lung Diseases: Regulative Role of IL-1 and PGE2

Elizabeth Fireman 1,✉, Shlomo Ben Efraim 2, Joel Greif 1, Hava Peretz 3, Shmuel Kivity 1, Marcel Topilsky 4, Yosef Rodrig 4, A Yellin 5, Ron N Apte 6
PMCID: PMC2365581  PMID: 18475594

Abstract

Fibroblasts (Fb) from patients with sarcoidosis (SA) and hypersensitivity pneumonitis (HP) exhibited a lower proliferative capacity compared with Fb obtained from control (CO) and diffuse interstitial fibrosis patients (DIF). Proliferation of Fb from SA or lip patients was suppressed by autologous LPS-stimulated alveolar macrophages (AM) supernatants but not by those from CO patients. Similarly, alveolar macrophages (AM) derived supernatant, obtained from CO, did not suppress the proliferation of SA and HP Fb. AM from SA and HP patients secreted higher amounts of IL-1α and β compared with controls and compared with Fb from SA and HP patients. Steady levels of IL-1α and βmRNA were expressed in unstimulated and stimulated cultures. Fb from SA and HP patients could be stimulated by LPS to secrete significantly higher levels of PGE2 than those detected in supernatants from LPS stimulated Fb of DIF patients. Only the proliferation of Fb from SA and HP patients was sensitive to amounts of IL-1 equivalent to those detected in the lung of these diseases. As SA and HP are two diseases where irreversible deterioration occurs in only 20% of the patients, we hypothesize that mediators in the lung may modulate Fb proliferation. IL-1 of AM origin and PGE2 of Fb origin secreted at high levels, may be candidates for this suppression because it was abrogated by anti IL-1β and indomethacin.

Full Text

The Full Text of this article is available as a PDF (797.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjrök P., Ohlsson K. The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse. Mediators Inflamm. 1992;1(1):27–31. doi: 10.1155/S0962935192000061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carter D. B., Deibel M. R., Jr, Dunn C. J., Tomich C. S., Laborde A. L., Slightom J. L., Berger A. E., Bienkowski M. J., Sun F. F., McEwan R. N. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature. 1990 Apr 12;344(6267):633–638. doi: 10.1038/344633a0. [DOI] [PubMed] [Google Scholar]
  3. Croute F., Delaporte E., Bonnefoy J. Y., Fertin C., Thivolet J., Nicolas J. F. Interleukin-1 beta stimulates fibroblast elastase activity. Br J Dermatol. 1991 Jun;124(6):538–541. doi: 10.1111/j.1365-2133.1991.tb04946.x. [DOI] [PubMed] [Google Scholar]
  4. De Jong F. A., Birch H. E., Schreiber G. Effect of recombinant interleukin-1 on mRNA levels in rat liver. Inflammation. 1988 Dec;12(6):613–617. doi: 10.1007/BF00914322. [DOI] [PubMed] [Google Scholar]
  5. Dinarello C. A. Interleukin-1 and its biologically related cytokines. Adv Immunol. 1989;44:153–205. doi: 10.1016/s0065-2776(08)60642-2. [DOI] [PubMed] [Google Scholar]
  6. Dunn C. J., Hardee M. M., Staite N. D. Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and Ifn gamma in mice. Agents Actions. 1989 Jun;27(3-4):290–293. doi: 10.1007/BF01972801. [DOI] [PubMed] [Google Scholar]
  7. Eisenberg S. P., Evans R. J., Arend W. P., Verderber E., Brewer M. T., Hannum C. H., Thompson R. C. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990 Jan 25;343(6256):341–346. doi: 10.1038/343341a0. [DOI] [PubMed] [Google Scholar]
  8. Gauthier F., Mouray H. Rat alpha2 acute-phase macroglobulin. Isolation and physicochemical properties. Biochem J. 1976 Dec 1;159(3):661–665. doi: 10.1042/bj1590661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gauthier F., Ohlsson K. Isolation and some properties of a new enzyme-binding protein in rat plasma. Hoppe Seylers Z Physiol Chem. 1978 Aug;359(8):987–992. doi: 10.1515/bchm2.1978.359.2.987. [DOI] [PubMed] [Google Scholar]
  10. Granowitz E. V., Clark B. D., Mancilla J., Dinarello C. A. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem. 1991 Aug 5;266(22):14147–14150. [PubMed] [Google Scholar]
  11. Hannum C. H., Wilcox C. J., Arend W. P., Joslin F. G., Dripps D. J., Heimdal P. L., Armes L. G., Sommer A., Eisenberg S. P., Thompson R. C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 1990 Jan 25;343(6256):336–340. doi: 10.1038/343336a0. [DOI] [PubMed] [Google Scholar]
  12. Kampschmidt R. F., Upchurch H. F. Effect of leukocytic endogenous mediator on plasma fibrinogen and haptoglobin. Proc Soc Exp Biol Med. 1974 Jul;146(3):904–907. doi: 10.3181/00379727-146-38216. [DOI] [PubMed] [Google Scholar]
  13. Laurell C. B. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21–37. doi: 10.3109/00365517209102748. [DOI] [PubMed] [Google Scholar]
  14. Lewis E. J., Sedgwick A. D., Hanahoe T. H. In vivo changes in plasma acute phase protein levels in the rat induced by slow release of IL-1, IL-6 and TNF. Mediators Inflamm. 1992;1(1):39–44. doi: 10.1155/S0962935192000085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lonberg-Holm K., Reed D. L., Roberts R. C., Hebert R. R., Hillman M. C., Kutney R. M. Three high molecular weight protease inhibitors of rat plasma. Isolation, characterization, and acute phase changes. J Biol Chem. 1987 Jan 5;262(1):438–445. [PubMed] [Google Scholar]
  16. Nakajima K., Powers J. C., Ashe B. M., Zimmerman M. Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem. 1979 May 25;254(10):4027–4032. [PubMed] [Google Scholar]
  17. Ohlsson K., Björk P., Bergenfeldt M., Hageman R., Thompson R. C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990 Dec 6;348(6301):550–552. doi: 10.1038/348550a0. [DOI] [PubMed] [Google Scholar]
  18. Pizzo S. V., Mast A. E., Feldman S. R., Salvesen G. In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim Biophys Acta. 1988 Nov 17;967(2):158–162. doi: 10.1016/0304-4165(88)90005-0. [DOI] [PubMed] [Google Scholar]
  19. Scuderi P., Nez P. A., Duerr M. L., Wong B. J., Valdez C. M. Cathepsin-G and leukocyte elastase inactivate human tumor necrosis factor and lymphotoxin. Cell Immunol. 1991 Jul;135(2):299–313. doi: 10.1016/0008-8749(91)90275-g. [DOI] [PubMed] [Google Scholar]
  20. Sternberger L. A., Hardy P. H., Jr, Cuculis J. J., Meyer H. G. The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem. 1970 May;18(5):315–333. doi: 10.1177/18.5.315. [DOI] [PubMed] [Google Scholar]
  21. Tilg H., Trehu E., Atkins M. B., Dinarello C. A., Mier J. W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994 Jan 1;83(1):113–118. [PubMed] [Google Scholar]
  22. Zoja C., Wang J. M., Bettoni S., Sironi M., Renzi D., Chiaffarino F., Abboud H. E., Van Damme J., Mantovani A., Remuzzi G. Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol. 1991 Apr;138(4):991–1003. [PMC free article] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES